COVID antibody drugs from Lilly and Regeneron won’t do much to boost their top lines: analysts
When Eli Lilly won emergency use authorization for its COVID-19 antibody drug, bamlanivimab, earlier this week, beating Regeneron to the finish line in a closely watched race, it was viewed as both good news and bad news. Now that Wall Street analysts have had a couple of days to digest the approval, some have concluded… Read More »